



## UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

September 3, 2025

HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:

### **H.C. Wainwright 27th Annual Global Investment Conference**

Date: Tuesday, September 9, 2025

Format: 1x1 Investor Meetings Only

### **Morgan Stanley 23rd Annual Global Healthcare Conference**

Date: Wednesday, September 10, 2025

Format: Fireside Chat Time: 2:35 PM - 3:10 PM EST and 1x1 Investor Meetings

### **About vTv Therapeutics**

vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by *cadisegliatin*, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at [vtvtherapeutics.com](http://vtvtherapeutics.com) or follow the company on [LinkedIn](#) or [X](#).

### **Investor Contact**

John Fraunces

LifeSci Advisors, LLC

[jfraunces@lifesciadvisors.com](mailto:jfraunces@lifesciadvisors.com)

### **Media Contact**

Caren Begun

TellMed Strategies

201-396-8551

[caren.begun@tmstrat.com](mailto:caren.begun@tmstrat.com)



Source: vTv Therapeutics Inc.